New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, New Mexico 87106, USA.
Expert Opin Biol Ther. 2010 Mar;10(3):467-76. doi: 10.1517/14712591003604708.
Osteoporosis is a common skeletal disease that is associated with an imbalance in bone remodeling. Denosumab is an investigational fully human monoclonal antibody to receptor activator of NF-kappaB ligand (RANKL), a cytokine member of the TNF family that is the principal mediator of osteoclastic bone resorption.
The efficacy and safety of denosumab in the management of postmenopausal osteoporosis is evaluated by reviewing the published literature and presentations at scientific meetings through 2009.
This review focuses on the data on fracture risk reduction and safety endpoints of denosumab in the treatment of postmenopausal osteoporosis.
In postmenopausal women with osteoporosis, denosumab (60 mg by subcutaneous injection every 6 months) increased bone mineral density, reduced bone turnover markers, and reduced the risk of vertebral, hip and non-vertebral fractures. Denosumab was well tolerated with a safety profile generally similar to placebo. It is a promising emerging drug for the prevention and treatment of postmenopausal osteoporosis.
骨质疏松症是一种常见的骨骼疾病，与骨重建失衡有关。地舒单抗是一种研究用的完全人源单克隆抗体，针对核因子-κB 配体（RANKL）的受体激活剂，RANKL 是肿瘤坏死因子（TNF）家族的一种细胞因子成员，是破骨细胞骨吸收的主要介质。
通过查阅 2009 年以前发表的文献和科学会议上的报告，评估地舒单抗在绝经后骨质疏松症治疗中的疗效和安全性。
本篇综述重点介绍了地舒单抗治疗绝经后骨质疏松症的骨折风险降低和安全性终点的数据。
对于绝经后骨质疏松症的妇女，地舒单抗（皮下注射，每 6 个月 60mg）可增加骨密度，降低骨转换标志物，并降低椎体、髋部和非椎体骨折的风险。地舒单抗具有良好的耐受性，安全性与安慰剂大致相似。它是一种有前途的新兴药物，可用于预防和治疗绝经后骨质疏松症。
